Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $60.89.

A number of equities analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. RPg Family Wealth Advisory LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,886,000. Segall Bryant & Hamill LLC lifted its holdings in Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after buying an additional 49,856 shares in the last quarter. Retirement Systems of Alabama lifted its holdings in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after buying an additional 74,173 shares in the last quarter. South Street Advisors LLC bought a new position in shares of Halozyme Therapeutics during the third quarter worth about $9,812,000. Finally, Foster & Motley Inc. lifted its holdings in Halozyme Therapeutics by 118.6% in the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after acquiring an additional 12,630 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $57.33 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 52-week low of $34.36 and a 52-week high of $65.53. The business’s 50-day moving average price is $51.90 and its 200 day moving average price is $54.42. The firm has a market cap of $7.29 billion, a P/E ratio of 18.98, a P/E/G ratio of 0.44 and a beta of 1.25.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.